FLT3 and hepatocellular carcinoma: For example, studies on sorafenib (kinase inhibitor drug approved for the treatment of advanced renal cell carcinoma, advanced hepatocellular carcinoma, FLT3-ITD positive acute myeloid leukemia (AML), and radioactive iodine-resistant advanced thyroid carcinoma) reported two isolated cases of SCCs of the skin associated with taking this drug [24].